Sign In
Buy LPCN
$2.19
-0.0600 (-2.67%)
At Close: Jun 03, 2026
Lipocine Reports US Appeals Court Affirmed Decision By Patent Trial, Appeal Board
12:13pm, Thursday, 09'th Apr 2020Lipocine Announces US Court of Appeals for the Federal Circuit Affirms Decision of USPTO
12:00pm, Thursday, 09'th Apr 2020
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that the U.S. Court of Appeals for the Federal Circuit affirmed t
LPCN: Target Date: August!
10:00am, Monday, 06'th Apr 2020
By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT 2019 Operational and Financial Results On March 13, 2020 Lipocine (NASDAQ:LPCN) filed its fiscal year 2019 10-K and posted its
Lipocine Announces Outcome of Markman Hearing in Patent Infringement Suit Against Clarus
12:00pm, Thursday, 26'th Mar 2020
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that Judge William C. Bryson of the United States District Court
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
11:37am, Thursday, 19'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commen
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
12:00am, Thursday, 19'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
Lipocine Announces 2019 Year End Financial and Operational Results
12:00pm, Friday, 13'th Mar 2020
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, today announced financial results for the year ended December 31, 2019, and provided a corporate update.
Lipocine Announces TLANDO™ PDUFA Date of August 28, 2020
01:00pm, Wednesday, 04'th Mar 2020
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration ("FDA") acknowledged receipt of the resubmission of TLANDO New Drug
Lipocine Announces TLANDO PDUFA Date Of August 28, 2020
12:00am, Wednesday, 04'th Mar 202024 Healthcare Stocks Moving In Wednesday's Pre-Market Session
01:01pm, Wednesday, 26'th Feb 2020
Gainers
Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) stock moved upwards by 65.7% to $0.67 during Wednesday's pre-market session.
InflaRx, Inc. (NASDAQ: IFRX) stock...
Why Lipocine Inc.'s (NASDAQ:LPCN) CEO Pay Matters To You
05:07pm, Tuesday, 25'th Feb 2020
In 1997 Mahesh Patel was appointed CEO of Lipocine Inc. (NASDAQ:LPCN). First, this article will compare CEO...
Lipocine Announces $6 Million Registered Direct Offering Priced At-The-Market
01:30pm, Tuesday, 25'th Feb 2020
Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has entered into securities purchase agreements with certa
LPCN: Reanalysis Elicits Resubmission
09:25am, Tuesday, 25'th Feb 2020
By John Vandermosten, CFA NASDAQ:LPCN READ THE LATEST LPCN RESEARCH REPORT Lipocine (NASDAQ:LPCN) held its post action meeting with the FDA’s Division of Bone, Reproductive and Urologic Products in
